Dementia
Quantified Imaging's ASL MRI software boosts precision across the dementia spectrum: from screening and diagnosis, through to patient selection and treatment monitoring.
Quantified Imaging's multimodal approach blends both ASL perfusion and structural MRI features, yielding similar sensitivity to amyloid PET and far outclassing conventional volumetric analysis.
Tested on 484 subjects, QI's MRI delivers 3x greater sensitivity to differentiate disease severity compared to standard of care MRI, and approaching PET imaging which is many times more expensive.
Quantified Imaging's perfusion biomarkers offer a new way for clinicians to track how patients are responding to treatment, with an exceptionally strong correlation with the only outcome that matters - patient cognition.
Following a cohort of patients receiving treatment for Alzheimer’s disease, QI ASL MRI biomarkers show exceptionally high correlation with cognitive outcomes. This gives doctors and patients objective evidence on whether the treatment is working or not.
Quantified Imaging's perfusion biomarkers have strong predictive power for patient outcomes on amyloid therapy (lecanemab and donanemab). This ensures patients can be guided to the most suitable treatments, maximising outcomes and value-for-money whilst minimising unnecessary risk.
Following a cohort of patients receiving treatment for Alzheimer’s disease, QI ASL MRI biomarkers predict at baseline treatment outcomes. This helps ensure that treatments are given to those who will most benefit whilst minimising risk.
The gold standard in perfusion MRI //
// precision-guiding treatment// widening access to early diagnosis// improving trial endpoints// reducing contrast use// reducing radiation exposure
For further information or to arrange a demo, get in touch
